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The hemagglutinin protein (HA) on the surface of influenza virus is essential for viral entry into the host cells. The HA1 subunit
of HA is also the primary target for neutralizing antibodies. The HA2 subunit is less exposed on the virion surface andmore con-
served than HA1.We have previously designed an HA2-based immunogen derived from the sequence of the H3N2 A/HK/68 vi-
rus. In the present study, we report the design of an HA2-based immunogen from the H1N1 subtype (PR/8/34). This immunogen
(H1HA0HA6) and its circular permutant (H1HA6) were well folded and provided complete protection against homologous viral
challenge. Antisera of immunized mice showed cross-reactivity with HA proteins of different strains and subtypes. Although no
neutralization was observable in a conventional neutralization assay, sera of immunized guinea pigs competed with a broadly
neutralizing antibody, CR6261, for binding to recombinant Viet/04 HA protein, suggesting that CR6261-like antibodies were
elicited by the immunogens. Stem domain immunogens from a seasonal H1N1 strain (A/NC/20/99) and a recent pandemic strain
(A/Cal/07/09) provided cross-protection against A/PR/8/34 viral challenge. HA2-containing stem domain immunogens therefore
have the potential to provide subtype-specific protection.
Influenza virus, the causative agent of flu, is responsible for yearlyepidemics and frequent pandemics around the world. The virus
changes its geneticmakeup constantly to escape the immune pres-
sure from the host, causing fresh epidemics. The envelope of the
virus has twomajor glycoproteins: hemagglutinin (HA) and neur-
aminidase (NA). HA is a trimer of HA1 and HA2 dimers that are
produced by cleavage of the precursor HA0. The globular head
domain of the protein is composed exclusively of HA1 and is
involved in binding of the virus to host cell sialic acid receptors
leading to endosomal uptake of the virus into the cell. HA2, along
with regions of HA1, forms the membrane-proximal stalk that is
in a metastable conformation, poised to change its conformation
upon exposure to the low pH of the endosomes. This conforma-
tional change brings about fusion of viral and host endosomal
membranes and release of the viral contents into the cytoplasm
(25).
Antibodies (Abs) generated against the HA glycoprotein are
responsible for conferring protection against viral infection (12).
The antibodies generated against the HA protein during natural
infection are primarily directed against the exposed head domain
(35). Mutations or recombination events involving the HA and
NA genes lead to genetic drift and shift, giving rise to new viruses
that are not susceptible to previously acquired immunity by the
host. In order to be effective, vaccines have to match the currently
circulating viral strains, necessitating the production of new vac-
cines every season. Therefore, the search for a universal vaccine
that provides broader protection and alleviates the need for fre-
quent vaccination is ongoing.
A sequence analysis of the HA sequences from various strains
and subtypes reveals that HA2 is more conserved than the HA1
subunit (2, 19). However, the immune response primarily targets
the globular head domain (HA1), and HA2-directed antibodies
were not thought to contribute to neutralization of the virus (35).
In the recent past, several broadly neutralizing antibodies that are
directed against conserved epitopes in the stalk region of HA have
also been isolated (8, 20, 30, 34). These antibodies are capable of
binding not only several strains of viruses within the same HA
subtype but also strains of other subtypes belonging to the same
clade. These antibodies have been shown to have neutralizing ac-
tivity and provide cross-strain protection in animal models (21,
26). Monoclonal antibodies directed to the fusion peptide of HA2
have been shown to react with several subtypes of viruses (29). An
immunogen that focuses the immune response to the HA2 frag-
ment and elicits Abs against conserved stem epitopesmight there-
fore confer protection against multiple strains of the virus.
Although it is desirable to use the HA2 fragment as an im-
munogen, expressing HA2 in the absence of HA1 in Escherichia
coli results in a protein that adopts the low-pH conformation (5).
We have earlier shown that by retaining interacting HA1 residues
and introducingmutations that destabilize the low-pH conforma-
tion of the molecule, it is possible to design a stable immunogen
comprising theHA2 subunit of the A/HK/68 virus from theH3N2
subtype (2). Following up on this work, we have now designed
immunogens H1HA0HA6_PR8 and a circular permutant
H1HA6_PR8 from the influenza A/PR/8/34 virus (an H1N1 vi-
rus). These proteins, when recombinantly expressed in E. coli,
purified, and used as immunogens, provided protection against a
lethal homologous virus challenge. Sera from immunized animals
cross-reacted with recombinant HA proteins from several strains
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and subtypes of HA. Antisera from immunized guinea pigs
competed with a broadly neutralizing antibody, CR6261, showing
that the immunogens were capable of eliciting antibodies against
the conserved CR6261 epitope of the HA stalk. Stem domain im-
munogens from both a drifted seasonal flu strain (A/NC/20/99)
and a recent pandemic flu strain (A/Cal/07/09) protected immu-
nized mice from a lethal A/PR/8/34 viral challenge. This suggests
that HA2-based immunogens can provide cross-protection
against several strains within a subtype and play an important role
in pandemic preparedness.
MATERIALS AND METHODS
Modeling the low-pH form of HA2 fragment residues 51 to 103 from
A/PR8/34. The trimeric structure of the region of residues 51 to 103 of
HA2 from the PR/8/34 strain was modeled using the program Modeler
9v4 (9, 24). The corresponding fragments from the low-pH structure of
HK/68HA (ProteinData Bank [PDB] ID 1htm)were used as the template
for the homology modeling.
Cloning, expression, and purification of the proteins. E. coli codon
optimized genes for H1HA6_PR8 and H1HA0HA6_PR8 were synthe-
sized. The genes for H1HA6_PR8, H1HA6_NC99, and H1HA6_Cal09
were cloned into pET-26b() between NdeI and HindIII sites. The
H1HA0HA6_PR8 gene was cloned into pET-28a() between NdeI and
BamHI sites. Cloning resulted in addition of a 6-His tag in all the con-
structs. BL21(DE3) cells transformed with the plasmids were grown in 2
liters Terrific broth to anA600 of 0.8 at 37°C and inducedwith 1mM IPTG
(isopropyl--D-thiogalactopyranoside). The cells were harvested after 6 h
of induction and lysed by sonication in 20 mM Tris (pH 8.0). The cell
lysate was centrifuged at 18,500  g, 4°C. The pellet was washed with
0.05%Triton X-100 in 20mMTris (pH 8.0) followed by centrifugation at
18,500  g, 4°C. The pellet was solubilized using 8 M guanidine hydro-
chloride (GdnHCl) in 20 mM Tris (pH 8.0). Solubilized and clarified
inclusion bodies were passed over an Ni-NTA column (GE Health Care)
at room temperature (RT) and eluted in 1MGdnHCl, 500mM imidazole,
20 mM Tris (pH 8.0). The proteins were then refolded by dialysis against
deionized water and stored at80°C.
CD spectroscopy. All spectra were acquired at 298 K. The circular
dichroism (CD) spectra of the proteins at a concentration of 5 M were
recorded in 1 phosphate-buffered saline (PBS) on a JASCO J-715 Spec-
tropolarimeter. The spectra were recorded using a 0.1-cm-path-length
cuvette by scanning from 250 nm to 195 nm at a rate of 50 nm/min with a
spectral bandwidth of 2 nm, response time of 4 s, and scan rate of 50
nm/min. Each spectrum is an average of 3 scans and is subtracted for
buffer control. Mean residue ellipticities (MRE) were calculated as de-
scribed previously (18).
Fluorescence spectroscopy.The intrinsic fluorescence emission spec-
trum of the proteins at a concentration of 2 M was recorded using a
1-cm-path-length cuvette under native (20 mMTris, pH 8.0) or denatur-
ing conditions (6 MGdnHCl, 20 mMTris, pH 8.0) after excitation at 280
nm on a Fluoromax-3 fluorimeter. The emission spectra were recorded
between 300 and 400 nm at 25°C using excitation and emission band-
widths of 3 nm and 5 nm, respectively. Each spectrum is an average of 3
scans and has been corrected for buffer fluorescence acquired under the
same conditions.
RP-HPLC. The oxidation state of the proteins was investigated using
reverse-phase high-performance liquid chromatography (RP-HPLC).
Each protein (50 M each) in 4 M GdnHCl, 50 mM Tris, pH 8.0, either
with or without 500 M Tris(2-carboxyethyl) phosphine (TCEP) was
injected onto an analytical RP C5 (15-cm by 4.6-mm) column and eluted
using a gradient of water and acetonitrile at a flow rate of 1 ml/min (40%
to 65% acetonitrile).
Size exclusion chromatography. The oligomeric state of the proteins
was investigated using size exclusion chromatography. H1HA6_PR8 and
H1HA0HA6_PR8 (200g and 100g, respectively), were loaded onto an
analytical Superdex-200 (10- by 300-mm) column (GE Healthcare) at
concentrations of 1 mg/ml and 0.5 mg/ml in PBS (pH 7.4) at 25°C. The
proteins were eluted in PBS (pH 7.4) at a flow rate of 0.5 ml/min, and the
elution profiles were monitored by measuring the absorbance at 220 nm.
Proteins used for calibration were thyroglobulin (669 kDa), ferritin (440
kDa), -amylase (200 kDa), conalbumin (75 kDa), and RNase A (13.7
kDa).
Animal immunization and challenge studies. Female BALB/c mice
(4 to 5 weeks old) were obtained from Charles River Laboratories (Wil-
mington, MA). Sets of 10 mice per immunogen were immunized intra-
muscularly with 20 g H1HA6_PR8, 20 g H1HA0HA6_PR8, 20 g
H1HA6_NC99, or 20 g H1HA6_Cal09 along with 100 g CpG7909
adjuvant (TriLinkBioTechnologies, SanDiego, CA).Naïvemice andmice
injected with adjuvant (100 g CpG7909) alone were used as controls.
Mice immunized once intranasally with 0.1 90% lethal dose (LD90) of
A/PR/8/34 acted as a positive control. The mice either were boosted with
a repeat dose of the immunogens 4 weeks later (prime and boost groups)
or were not boosted (prime only groups). Three weeks after the booster,
the mice were intranasally challenged with 20 l of 3.6 107 50% tissue
culture infective dose (TCID50)/ml (1 LD90) of homologous A/PR/8/34
virus. In order to test for protection against a higher dose of the virus, one
group of mice that were primed and boosted with H1HA6_PR8 were
challenged with a 3 LD90 dose of homologous PR8 virus. The body weight
and survival of the mice were monitored for the next 20 days.
For evaluation of protection against viral replication in the lungs,mice
were immunized with the prime-boost regimen as described above and
challenged intranasally 3 weeks later with a sublethal dose of A/PR/8/34
(0.1 LD90). Lungs were isolated at days 2, 4, 6, 8, and 10 postchallenge and
used for determination of viral titers.
For generation of guinea pig antiserum, female guinea pigs (250 to 350
g; Charles River Laboratories) were immunized intramuscularly with 100
g of H1HA6 or H1HA0HA6 formulated with 250g/ml CpG7909 (Tri-
Link BioTechnologies) in 400 l. The immunizations were given three
times at 4-week intervals. Blood samples were collected 3 weeks after each
injection, and sera were stored at70°C until use. All animals weremain-
tained in the animal facilities of Merck Research Laboratories in accor-
dance with IACUC guidelines.
Determination of anti-HA6 serum antibody titers. HA6 proteins
were immobilized on 96-well Nunc plates at 2 g per ml in 50 l PBS at
4°C overnight. Plates were washed six times with PBS containing
0.05%Tween 20 (PBST) and blocked with 3% skim milk in PBST. Sera
were diluted starting at 1:100 anddiluted in a 4-fold series inmilk-PBST in
a volume of 100 l per well. Plates were incubated for 2 h at room tem-
perature followed by six washes with PBST. Horseradish peroxidase
(HRP)-conjugated goat anti-mouse secondary antibody (Invitrogen) in
milk-PBST (at 1:5,000 dilution) was added (50l per well) and incubated
at room temperature for 1 h. Plates were washed six times followed by
addition of 100l per well of the substrate 3,3=,5,5=-tetramethylbenzidine
(Virolabs, Inc.) and stopped after 3 to 5 min of development. The anti-
body titer was defined as the reciprocal of the highest dilution that gave an
optical density at 450 nm (OD450) value above the mean plus 2 standard
deviations.
Determination of lung viral titers.Mouse lungwas homogenized in 3
ml Dulbecco’s modified Eagle medium (Invitrogen, Grand Island, NY)
containing 0.1% bovine serum albumin (Sigma-Aldrich Corp, St. Louis,
MO) (DMEM-BSA). The virus titers were determined by plaque assay on
Mardin-Darby canine kidney (MDCK) cells according to the method de-
scribed in reference 17. Briefly, MDCK cells were cultured in 6-well plates
in DMEM supplemented with 10% fetal bovine serum (HyClone, Logan,
UT). Two hundred microliters of serially diluted test samples were added
to each well of 6-well plates containing confluent MDCK cells. The plates
were incubated at 37°C for 1 h. After the incubation, the samples were
removed, and the cells were overlaid with 3 ml per well of 0.9% agar (BD
Biosciences, San Jose, CA) in DMEM-BSA supplemented with 1 g/ml
TPCK (tolylsulfonyl phenylalanyl chloromethyl ketone)-treated trypsin
(Sigma-Aldrich). After 4 days of incubation at 37°C and 5%CO2, the agar
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overlays were removed and the cells were fixed and stained with 10%
glutaric dialdehyde (Sigma-Aldrich) and 0.67% crystal violet (Sigma-
Aldrich) in water. Plaques were counted. All samples were tested in du-
plicates.
Binding of antisera to recombinant HA proteins. Binding of anti-
H1HA6_PR8 and anti-H1HA0HA6_PR8 sera to various recombinantHA
(rHA) proteinswasmeasured using enzyme-linked immunosorbent assay
(ELISA). Briefly, 250 ng of HA proteins from Protein Science Corp. (Viet/
1203/04,NewCaledonia/20/99, and pandemicH1N1California/04/09) as
well as H1HA6_PR8 and H1HA0HA6_PR8 proteins was immobilized on
Nunc 96-well plates and blocked with 1% BSA in PBST (phosphate-buff-
ered saline [pH 7.4] containing 0.5% Tween 20). Serial dilutions of sera
(50 l) were added to the wells and incubated for 4 h. The plates were
washed with PBST thrice and probed with alkaline phosphatase (ALP)
conjugated anti-mouse Ab (1:10,000 diluted) for 2 h. After washing excess
secondary Ab, the plates were developed by adding ALP substrate (p-
nitrophenyl phosphate-alkaline phosphatase Yellow Liquid substrate
from Sigma) and read in a plate reader at 405 nm after 1 h.
Competition experiments with CR6261. Sector Imager 6000 96-well
plates (Meso Scale Discovery, Gaithersburg, MD) were coated with 50
l/well of 0.2 g/ml recombinant A/Vietnam/1203/2004 HA diluted in
PBS. The plates were washed with PBST and blocked with 3% dry milk
(LabScientific, Livingston, NJ) in PBST. Monoclonal antibody (MAb)
CR6261 at 100 ng/ml was mixed with an equal volume of serial dilutions
of the test guinea pig serum. To each well, 50l of themixture was added,
and the plates were incubated at room temperature for 1 h. Plates were
washed with PBST, and 100 l of Meso Scale Discovery Sulfo-tag-labeled
goat anti-human IgG at 0.5 g/ml in PBST containing 3% dry milk per
well was added and incubated at room temperature for 1 h, which was
followed with an additional wash and addition of 150 l of Meso Scale
Discovery read buffer T per well. The plates were read with Sector Imager
6000. All samples were run in duplicates. Percent competition was calcu-
lated as follows: % Competition  [(A  P)/A] * 100, where A is the
binding of CR6261 toHA in the absence of H1HA6 antiserum and P is the
binding of CR6261 to HA in the presence of H1HA6 antiserum.
The luminescence signal from a Sector Imager was used as a measure
of binding in the above equation.
Sequence analysis of HA proteins from PR8, NC99, and Cal09 vi-
ruses. To identify conserved regions in the HA stem of PR8, NC99, and
Cal09 viruses, a sequence comparisonwas done.HA sequences of PR8 and
NC99 or Cal09 were aligned using ClustalX, and residue-wise sequence
identity was mapped onto the structure of HA (PDB ID 1ru7).
Binding to broadly neutralizing antibody CR6261 by surface plas-
mon resonance (SPR). CR6261 IgG (1,500 relative units [RU]) was
immobilized onto a CM-5 Biacore Sensor chip surface using standard
amine coupling, and binding of rHA A/Cal/07/2009 (Protein Science
Corp.), H1HA6_PR8, and H1HA0HA6_PR8 to this MAb was recorded
at 25°C on a Biacore 2000 optical biosensor (Biacore, Uppsala, Swe-
den). Proteins were passed over the sensor surface at a flow rate of 30
l/min in PBS (pH 7.4) containing 0.01% surfactant P20, and the
association and dissociation were measured for 100 s and 200 s, respec-
tively. The reported binding is subtracted for nonspecific binding to
the control protein ovalbumin under the same conditions. The off-
rates for H1HA6_PR8 and H1HA0HA6_PR8 were fitted in biphasic
mode (double exponential decay) using the equation y a1e
(k1 · t)
a2e
(k2 · t), where a1 and a2 are the respective amplitudes and k1 and k2
are the respective dissociation constants of phase 1 and phase 2, y is
the RU, and t is the time in seconds during the dissociation phase.
The fractional amplitudes fa1 and fa2 are given by a1/(a1  a2)
and a2/(a1  a2), respectively. The off-rate for rHA was monophasic
(a1 0, fa2 1). All analyte concentrations are given in trimer units,
as the binding stoichiometry is 1 mol of HA trimer per immobilized
CR6261 paratope.
RESULTS AND DISCUSSION
Design. To design a stem-derived immunogen based on the se-
quence of the A/PR/8/34 virus from the H1N1 subtype, the acces-
sibilities of all residues in the PR8 HA structure (PDB ID 1ru7)
(11)were calculated, andHA1 fragments that interactedwithHA2
were identified using the program PREDBURASA (16). The HA1
residue number 1 according to PDB 1ru7 numbering corresponds
to residue number 14 in the full-length HA sequence with the
signal peptide (sequence ID gi 194304803). Residues 1 to 160 of
HA2 have been numbered from 501 to 660 in the PDB. We have
used the PDB 1ru7 numbering when referring to residues in the
constructs. The accessibilities of all residues in the HA1 chain in
the presence and absence of the HA2 chain were calculated. HA1
residues that have a difference of 5 Å2 ormore in accessible surface
area (ASA) in the above calculation and a 10% or higher accessi-
bility difference were considered to be interacting with HA2. The
list of interacting residues consisted of residues 5 to 14, 21 to 24, 32
to 36, 102 to 107, 265 to 268, 292 to 295, and 300 to 325 of HA1.
Three fragments ofHAwere included in the immunogen: residues
501 to 672 ofHA2 and residues 1 to 41 and 290 to 325 ofHA1 (Fig.
1A). The fragments containing residues 102 to 107 and 265 to 268
of HA1 interact with the loop connecting the helices 4 and 5.Most
of the interacting residues were polar ones, and these fragments
were not included in the design. Next, accessibilities of all residues
in the above fragments were calculated in the presence and ab-
sence of the rest of HA in order to identify residues that had be-
come exposed in the fragments upon removal of the rest of HA.
These residues were 41H, 290N, 298I, 299H, 301V, 303I, 304G,
305E, 306C, and 307P of HA1 and 564T, 566V, 568K, 569E, and
571N of HA2. Of these residues, the nonpolar residues that had a
large change in ASA were mutated employing the program Roset-
taDesign (15), as increase in the exposed hydrophobic surface
would be destabilizing for the protein. Exposure of polar residues
on the surface is not expected to affect the stability of the protein.
At individual positions that were identified for mutation, all
polar amino acid mutations were made using the RosettaDesign
module. The structures and energies of the generatedmodels were
analyzed, and the best possible mutation for each position was
chosen. For residues that were in close proximity in the structure,
the calculations were repeated by mutating residues simultane-
ously at these positions. The mutations were chosen in a manner
to ensure that there were no unfavorable electrostatic interactions
because of their introduction. The final set of mutations was
I298T, V301T, I303N, and C306S (in HA1) and V566T (in HA2).
In addition to the above mutations, in order to destabilize the
low-pH conformation of HA, mutations F63D and L73D were
introduced in the loop joining the helices 4 and 5 of HA2. As the
low-pH structure is available only for HA from A/HK/68 (3), res-
idues 51 to 103 of the PR/8/34HA2weremodeled using this struc-
ture (PDB ID 1htm) as the template with the programModeler (9,
24). The residues 63F and 73L are buried and are in close contact
in the low-pH model, while they are exposed in the neutral-pH
form (Fig. 1B and C). When Asp residues are introduced, the
low-pH form should be destabilized, as formation of the low-pH
trimeric structurewould result in burial of chargedAsp residues in
the hydrophobic interior (residues 63 and 73 ofHA2 are predicted
to be at positions a and d of the extended coiled coil present in the
low-pH structure).
Constructs H1HA6_PR8 andH1HA0HA6_PR8were based on
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the A/PR/8/34 HA sequence (sequence ID gi 194304803) taken
from the influenza virus resource at NCBI (1). The three chosen
fragments were connected by flexible linkers in two ways. The
length of the linkers was decided based on the C-C distances
between the residues to be connected in the crystal structure (PDB
ID 1ru7), and the sequence consisted of repeats of the tripeptide
GSA. These linkers have been used previously by us in other pro-
tein designs (33), are expected to be soluble and flexible, and
should not disrupt the structure of the fragments they link.
The construct H1HA0HA6_PR8 was made by connecting the
C terminus of the secondHA1 fragment (residues 290 to 325)with
theN terminus ofHA2 using the natural linker sequence (residues
326 to 330) present in HA0. The cleavage site residue 330R was
mutated to Q in order to abolish trypsin cleavage. A mutation of
cleavage site residue to Q at the cleavage site of HK/68 HA was
previously shown to result in an uncleavable precursor of HA (4).
This molecule did not undergo the low-pH conformational
change even upon exposure to low pH. It has been shown that
cleavage of the precursor to HA1 and HA2 fragments and disso-
ciation of the HA1 domain fragment is essential for the low-pH
conformationalchangeandviralpathogenicity(13).H1HA0HA6_
PR8 has residues 3 to 41 of HA1, a 3-amino-acid linker (GSA),
residues 290 to 330 of HA1 with cleavage site residue 330R
changed toQ (to abolish trypsin cleavage), and residues 501 to 660
of HA2.
In the construct H1HA0HA6, the fusion peptide is expected to
be exposed (by comparison with the precursor HA0 structures of
HK/68 [PDB ID1ha0]).However, the conformation of this region
is different in the 1918H1N1HA0 (PDB ID1rd8) and the cleavage
site loop abuts the HA surface (28). In order to avoid problems
that might arise due to the exposure of the hydrophobic fusion
peptide, the circular permutantH1HA6_PR8wasmade. This con-
struct contains the same fragments as H1HA0HA6_PR8 joined
together with linkers in a different manner (Fig. 2). The HA2
subunit has been placed at the N terminus of this molecule. The
fusion peptide would therefore be buried when themolecule folds
into the desired neutral-pH conformation and is expected tomore
closely mimic the stem region of the native trimer. The construct
H1HA6_PR8 has residues 501 to 672 of HA2, a 6-amino-acid
linker (GSAGSA), residues 1 to 41 of HA1, and a 3-amino-acid
linker (GSA), followed by residues 290 to 325 of HA1. In the
crystal structure of the PR/8/34 HA (PDB ID 1ru7) residues be-
yond 660 of HA2 are disordered. Hence, the residues to be con-
nected and linker length for the H1HA6_PR8 construct were de-
cided based on the HK/68 HA structure (PDB ID 1hgd).
In order to test for the ability of HA stem immunogens to elicit
cross-protection against multiple strains of viruses, immunogens
based on the sequences of twoH1N1 viruses with different degrees
of HA sequence identity to A/PR/8/34 were designed. The alter-
native approach of immunizing with H1HA6_PR8 and carrying
out a heterologous challenge with seasonal or pandemic H1N1
was not attempted because of lack of availability of appropriate
mouse-adapted challenge strains other than A/PR/8/34. Stem do-
main immunogens similar to H1HA6_PR8 were made from HA
proteins of these viruses. The design of H1HA6_NC99 was based
on the sequence of A/New Caledonia/20/99 HA (sequence ID gi
9849784), which has an identity of 88% with PR8 HA. The design
of H1HA6_Cal09 was based on A/Cal/07/09 HA (sequence ID gi
227831808), which has an identity of 82%with PR8HA. Residues
corresponding to those in H1HA6_PR8 were chosen for the de-
FIG 1 Structures of the A/PR8/34 HA ectodomain (A) and HA2 fragment residues 51 to 103 at neutral pH (B) and low pH (C). (A) The colored regions are
fragments included in the H1HA6 design (HA2 chains are shown in blue and HA1 in green). The globular head domain that is not part of H1HA6 is shown in
gray. The residues constituting the epitope for the broadly neutralizing antibody CR6261 are a part of H1HA6 (the epitope is in orange). (B and C) Residues 57
to 75 ofHA2 are shown in pink. These residues form the loop between helices 4 and 5 at neutral pH and form a part of the extended coiled coil at low pH. Residues
63F (green) and 73L (blue) of HA2 are exposed in the neutral pH conformation, while they are buried in the trimeric core of the coiled coil at low pH. The
neutral-pH structure (B) has been taken from the full-length neutral-pH structure of PR8/34 HA (PDB ID 1ru7). This region corresponds to residues 551 to 603
of the HA2 chains in this PDB. The low-pHmodel (C) has been generated by homologymodeling using the programModeler. The images were generated using
Rasmol (21).
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sign. The mutations that were introduced in H1HA6_PR8 to re-
move hydrophobic patches and to destabilize the low-pH form
were introduced in these constructs. Additionally, residue 305E
(HA1) was mutated to Q (in H1HA6_NC99) or K (in H1HA6_
Cal09) to prevent repulsion with 563D of HA2. Residue 566V
(HA2) was not changed in H1HA6_Cal09, as this residue was
buried and packedwith other residues in its vicinity (PDB ID3lzg)
(37).
The final sequences of the designed proteins (after incorpora-
tion of mutations to destabilize the low-pH structure and to in-
crease solubility) are given in Fig. 2. The H1HA6 design is very
similar to the one described earlier for anH3N2HA (2). However,
the design H1HA0HA6 has not been tested before. A headless HA
construct from A/PR/8/34 (expressed in 293T cells incorporated
into virus-like particles [VLPs]) described earlier has a connectiv-
ity similar to that of H1HA0HA6 (27).
Expression, purification, and biophysical characterization.
The proteins H1HA6_PR8, H1HA0HA6_PR8, H1HA6_NC99,
and H1HA6_Cal09 were expressed in E. coli under the control of
the T7 promoter and purified from inclusion bodies byNi-affinity
chromatography under denaturing conditions. The proteins were
refolded by dialysis against water. The yield was 2 to 3 mg/liter for
each of the proteins. Far-UV CD spectra of the purified proteins
indicated that they were well folded and were largely helical
(Fig. 3A). A shift in the emission maxima of the intrinsic fluores-
cence of the proteins from 345 nm to 357 nm upon denaturation
indicated that the proteins were well folded and compact under
native conditions (Fig. 3B). Mass spectrometric analysis of
H1HA6_PR8 revealed that there were two species: the full-length
protein and the N-terminal Met-cleaved form. The observed
masses correspond to the fully oxidized forms in both species with
a deficit of 4 Da compared to the reduced protein. This corre-
sponds to the formation of two disulfide bonds (expected masses,
30,258.3 Da for the N-terminal Met-cleaved protein and 30,389.4
Da for the full-length protein; observed masses, 30,258.3 Da and
30,385.4 Da, respectively).
Reverse-phase HPLC studies indicated that the proteins
H1HA6_PR8 and H1HA0HA6_PR8 were oxidized and the native
disulfide bonds are formed as is expected in properly folded HA
(Fig. 3C). Oxidized H1HA6_PR8 eluted primarily as a single peak
on the reverse-phase HPLC. Upon reduction, the peak eluted at
higher acetonitrile. This is expected because reduction should lead
to greater exposure of the hydrophobic surface. H1HA0HA6_PR8
was partially aggregated because of intermolecular disulfide bonds
and showed twomajor peaks in the oxidized state. The aggregates
were removed upon reductionwith the reducing agent TCEP. The
crystal structure ofHK/68HA in theHA0precursor form revealed
that the highly hydrophobic fusion peptide was exposed and the
cleavage site at the junction of the HA1 and HA2 was accessible
(4). This resulted in a surface cavity in the HA0 molecule that is
otherwise filled with the fusion peptide in the postcleavage neu-
tral-pH form (35). In the H1HA0HA6_PR8 design, the HA1 and
HA2 fragments have been connected using the natural linker pres-
ent in the HA mimicking the HA0 form.
The apparent molecular weight and oligomeric state of
H1HA6_PR8 and H1HA0HA6_PR8 were assessed by analytical
size exclusion chromatography (Fig. 4) experiments. The data in-
dicated that H1HA6_PR8 is likely to be largely trimeric in solu-
tion, whereas a substantial proportion of H1HA0HA6 forms
higher-molecular-weight aggregates. The higher aggregation pro-
pensity of H1HA0HA6_PR8 relative to H1HA6_PR8 is probably
due to the exposed hydrophobic fusion peptide and the cavity
FIG 2 Connectivity and sequences of the designed constructs. H1HA0HA6 consists of residues 3 to 41 of HA1, a 3-amino-acid linker (GSA), residues 290 to 330
ofHA1with cleavage site residue 330R changed toQ (to abolish trypsin cleavage), and residues 501 to 660 ofHA2. The circular permutantH1HA6design consists
of residues 501 to 672 of HA2, a 6-amino-acid linker (GSAGSA), residues 1 to 41 of HA1, and a 3-amino-acid linker (GSA) followed by residues 290 to 325 of
HA1. Mutations were incorporated into the constructs to stabilize the neutral pH conformation (in bold) and to remove exposed hydrophobic patches. The
sequences of H1HA0HA6_PR8 (1), H1HA6_PR8 (2), H1HA6_NC99 (3), and H1HA6_Cal09 (4) are given. Mutated residues are underlined, and linkers and
vector-derived sequences are shown in italics. The numbering scheme is the same as in the PDB ID 1ru7. The box diagrams above the sequences show the way
in which the HA fragments have been connected. The lengths of the fragments are not to scale.
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described above. The circularly permuted H1HA6_PR8 design
seems to be better than theH1HA0HA6_PR8 design for the above
reason.
Immunization and challenge. Details of the immunization
schedule and survival after challenge are presented in Table 1.
H1HA0HA6_PR8 and H1HA6_PR8 were used to immunize
BALB/c mice, and both constructs were highly immunogenic as
inferred from the postdose 2 (PD2) titers (Fig. 5A and B). At week
7, 3 weeks after the second immunization, mice were challenged
with 1 LD90 of A/PR/8/34 virus. Themice lost weight initially after
the challenge but later recovered completely (Fig. 6B). Both im-
munogens successfully protected mice from homologous viral
challenge (Fig. 6A), though the extent of weight loss was slightly
less for mice immunized with H1HA6. Immunization with
H1HA6_PR8 also provided significant protection against a higher
dose of the virus (3 LD90) (Fig. 6A). As a positive control, one
group was intranasally immunized with 0.1 LD90 of A/PR/8/34
virus.
Immunization with stem domain immunogens from drifted
viruses H1HA6_NC99 and H1HA6_Cal09 also protected mice
from lethal challenge by A/PR/8/34 virus (Fig. 6A). This indicates
that stem domain immunogens are capable of protecting against
several strains of viruses within the subtype, unlike conventional
vaccines that are ineffective against drifted viruses. However,mice
immunized with a single dose of H1HA6 immunogens suc-
cumbed to infection (Table 1). Immune responses generated by a
single-dose immunization are probably insufficient for protec-
tion.
We have previously shown (Table S1 in the supplemental ma-
terial in reference 2) that in all H1 strains the exposed residues in
the stem domain (H1HA6) are 90% conserved. In general, HA
proteins have 	80% sequence identity in the entire HA within a
subtype (14, 19, 22). Cal09 is one of the most divergent of the
FIG 3 Biophysical characterization of the designed stem domain immuno-
gens. (A) Far-UV CD spectra of H1HA6_PR8, H1HA0HA6_PR8, H1HA6_
NC99, and H1HA6_Cal09 (5 M each) in PBS, pH 7.4, at 25°C. (B) Fluores-
cence emission spectra of 2 M H1HA6_PR8 (black) and H1HA0HA6_PR8
(gray) under native conditions (20mMTris, pH 8.0) (solid line) or denaturing
conditions (6 M GdnHCl, 20 mM Tris, pH 8.0) (dashed line) at 25°C. Excita-
tion was at 280 nm. (C) Reverse-phase HPLC profiles of H1HA6_PR8 (in
black) and H1HA0HA6_PR8 (in gray). The reduced proteins (dashed lines)
have retention times that are different from those of the native proteins (solid
lines), indicating that the proteins are oxidized. H1HA6_PR8 shows a single
major oxidized peak in the native form, while H1HA0HA6_PR8 is partially
aggregated because of intermolecular disulfide bonds.
FIG 4 Gel filtration profile of H1HA6_PR8 (solid line) andH1HA0HA6_PR8
(dotted line) on a Superdex 200 analytical column in PBS, pH 7.4, at 25°C. The
inset shows the column calibration curve. A large fraction of the H1HA6_PR8
elutes at a volume that corresponds to its trimeric mass (peak 2, inverted
triangle in insert). However, a major fraction of H1HA0HA6_PR8 is aggre-
gated and elutes close to the void volume (peak 1), while a small fraction elutes
at a volume that corresponds to its monomeric mass (peak 3). The expected
trimeric mass of H1HA6_PR8 is 91.2 kDa, and the estimated mass for peak 2
from the calibration curve is around 90 kDa. The expectedmonomericmass of
H1HA0HA6_PR8 is 29.5 kDa.
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H1N1 strains compared to PR8 (the sequence identity between
HA proteins of these strains is 82%). An HA6 immunogen de-
signed fromCal09HA protected against lethal challenge with PR8
virus. Therefore, we expect an H1HA6 vaccine to protect against
the vast majority of H1 strains. In contrast, successive vaccine
strains have a sequence identity as high as 98% in the entire HA,
i.e., a 2% sequence variation in HA is sufficient to reduce the
efficacy of a conventional flu vaccine.
Lung viral titers. To further evaluate the effect of vaccine on
viral replication, two groups of mice were immunized either with
H1HA6_PR8 plus CpG7909 adjuvant or with the adjuvant alone.
Threeweeks after the second immunization,micewere challenged
intranasally with a sublethal dose of PR8 (0.1 LD90). Five mice
from each group were sacrificed at days 2, 4, 6, 8, and 10 postchal-
lenge, and the viral titers in the lungs were determined. Whereas
no difference between the two groups was observed at days 2 and
4, the vaccine group showed 1.5-log-lower titers (3 103 PFU/ml
versus 6.7 104 PFU/ml; P
 0.05) at day 6, and it had no detect-
able virus at day 8, when 4 of 5 mice in the control group still had
detectable virus. The data indicate that immunization with
H1HA6 was able to reduce lung viral replication.
Binding of antisera to HA proteins of various strains. ELISA
studies were carried out to examine binding of antisera from an-
imals immunized with H1HA6_PR8, H1HA0HA6_PR8, and in-
tranasal PR8 virus with HA proteins from various strains.
H1HA6_PR8 and H1HA0HA6_PR8 were highly immunogenic,
and antisera of immunized mice had titers of 106 against homol-
ogous antigens (Fig. 5A and B). Sera frommice immunized intra-
nasally with 0.1 LD90 of PR8 virus had 100-fold-lower titers
against H1HA6_PR8 and H1HA0HA6_PR8 (Fig. 5C). The HA1
subunit of the HA protein forms an exposed globular head do-
main that contains the receptor binding site. Most antibodies in-
duced by natural viral infection are directed against this domain
(35). The lower anti-H1HA6_PR8 titers (reflective of anti-HA2
titers) in animals immunized with whole PR8 virus are consistent
with this observation.
Anti-H1HA6_PR8 sera reacted strongly with recombinant HA
proteins from all other strains tested (Fig. 5A; Table 2). The titers
are consistent with the sequence identity of these proteins and
A/PR/8/34 HA (NC/99 [identity in HA1, 83%, and in HA2, 96%]
FIG 5 Anti-HA titers in sera from H1HA6_PR8, H1HA0HA6_PR8, and PR8
virus-immunized mice. ELISA titers of anti-H1HA6_PR8 sera (A), anti-
H1HA0HA6_PR8 sera (B), and virus-immunized sera (anti-PR8, adminis-
tered intranasally) (C) against H1HA6 (), H1HA0HA6 (Œ), rHA H5N1
Vietnam/1203/04 (Viet/04) (), rHA H1N1 New Caledonia/20/99 (NC/99)
(o), rHA pandemic H1N1 California/4/09 (Cal/09) (), and negative control
(ovalbumin) (). Cross-reactive titers decrease in the following order: anti-
H1HA6_PR8 sera	 anti-H1HA0HA6_PR8 sera	 anti-PR8 sera.
TABLE 1 Immunization dose regimen used for challenge studies
Group
Vaccine antigen/adjuvant (time of
immunization)
%
Survivala
Log10
anti-HA6
titerb
1 20 g H1HA0HA6_PR8/100 g
CpG7909 (wk 0 and wk 4)
100 NDc
2 20 g H1HA6_PR8/100 g CpG7909
(wk 0 and wk 4)
100 5.0
3 20 g H1HA6_NC99/100 g
CpG7909 (wk 0 and wk 4)
90 4.5
4 20 g H1HA6_Cal09/100 g
CpG7909 (wk 0 and wk 4)
90 4.1
5 20 g H1HA6_PR8/100 g CpG7909
(wk 0 only)
20 3.6
6 20 g H1HA6_NC99/100 g
CpG7909 (wk 0 only)
10 3.0
7 20 g H1HA6_Cal09/100 g
CpG7909 (wk 0 only)
30 3.3
8 20 g H1HA6_PR8/100 g CpG7909
(wk 0 and wk 4)d
70 4.6
9 PR8 virus, 0.1 LD90, intranasal
(wk 0 only)
100 ND
10 100 g CpG7909 (wk 0 and wk 4) 30 ND
11 None 20 ND
a Each group consisted of 10 BALB/c mice. Mice were challenged with 1 LD90 of A/PR/
8/34 virus at week 7. The survival of the mice after viral challenge was monitored for 20
days postchallenge.
b Antibody titers of sera collected at week 6 (after dose 2) against recombinant HA
(A/PR/8/34) were measured by ELISA.
c ND, not determined.
d Mice in this group were challenged with 3 LD90 of A/PR/8/34 virus at week 7.
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	 pandemic strain Cal/09 [identity in HA1, 74.7%, and in HA2,
92%] 	 Viet/04 [identity in HA1, 4.7%, and in HA2, 79.7%]]).
Anti-H1HA0HA6_PR8 sera had measurably lower cross-reactive
titers thanH1HA6_PR8 sera (Fig. 5B). RP-HPLCand gel filtration
profiles of H1HA0HA6_PR8 showed that the protein is aggre-
gated. Lower cross-reactive titers in animals immunized with this
protein are observed, probably because of its aggregation-prone
nature. In animals immunized with PR8 virus, the cross-reactive
titers are 100-fold less than in H1HA6_PR8-immunized ani-
mals (Fig. 5C).While H1HA6_PR8 elicited high titers of antibod-
ies reactive against HA from both pandemic H1N1 and avian
H5N1, immunization with PR8 virus failed to elicit such antibod-
ies. Thus, by directing the immune response to theHA2domain of
the protein, higher cross-reactive titers are achieved. Computa-
tional redesigning and trimming of immunodominant epitopes
have been successfully used to focus immune responses to con-
served epitopes and identify broadly neutralizing Abs in other
highly variable viral proteins like HIV envelope (6, 36).
Competition experiments with broadly neutralizing anti-
body CR6261. Antisera from H1HA6-immunized mice were
tested in a standard microneutralization assay as described previ-
ously (2). H1HA6 antisera did not show neutralization in this
assay (data not shown). The 50% inhibitory concentration (IC50)
for CR6261 measured by us using this assay was 11.69 g/ml.
Earlier studies with an H3HA-derived HA6 protein (from the
HK/68 virus) in FcR knockout (KO) mice indicated that protec-
tion conferred by anti-HA6 antibodies is largely mediated by an-
tibody-dependent effector functions such as antibody-dependent
cell-mediated cytotoxicity (ADCC), although competition studies
indicated that neutralizing 12D1-like antibodieswere also likely to
contribute to the observed protection (2). In the present case also,
such effector functions are likely to contribute to the observed
protection.
Since the microneutralization assay is not very sensitive in de-
tecting stem-directed neutralizing antibodies, the presence of an-
tibodies to a known stem epitope (targeted by the broadly neutral-
izing antibody CR6261) was tested in a competition binding
experiment. Because of lack of sufficient supply of the mouse
serum, the competition assay was carried out with sera from im-
munized guinea pigs. Anti-H1HA6_PR8 sera and anti-
H1HA0HA6_PR8 sera were able to compete with CR6261 for
binding to recombinant Viet/04 HA (Fig. 7), indicating that
CR6261-like antibodies were elicited by immunizationwith stem-
derived immunogens. However, naïve sera and sera from animals
immunized with an HK/68 H3HA-derived stem immunogen (2)
did not show significant competition. Stem-directed neutralizing
antibodies like CR6261 mediate neutralization by inhibition of
viral and host membrane fusion, unlike head-directed antibodies,
which have hemagglutinin inhibition (HAI) activity and inhibit
viral binding to receptors on the host cells. The lack of neutraliza-
tion observed withH1HA6 sera suggests that the CR6261-like Abs
must be present at levels lower than the 11.69g/ml IC50 value for
CR6261.
Binding of H1HA6 proteins to broadly neutralizing Ab
CR6261. The binding of the designed immunogens to a broadly
neutralizing antibody, CR6261, was tested by SPR (Table 3 and
Fig. 8). Recombinant CR6261 was produced based on the pub-
lished sequence (32) in 293T cells. Recombinant HA from A/Cal/
07/09 bound the Ab with Kd (dissociation constant) of 6 nM,
which is similar to the value of 3.2 nM reported previously (31).
FIG 6 Survival and weight loss studies in mice immunized with H1HA6 and
H1HA0HA6 immunogens. (A) Percent survival after challenge with a lethal
dose of A/PR/8/34 virus; (B) fractional weight (%) of the surviving mice. Mice
immunized twice with H1HA6_PR8 and H1HA0HA6_PR8 were completely
protected against the homologous virus challenge (1 LD90). Prime boost im-
munization withH1HA6_PR8 also protected against a higher dose of the virus
(3 LD90 [3XLD90]). HA stem domain immunogens from two other H1N1
viruses provided cross-protection against PR8 challenge (1 LD90), showing
that stem domain immunogens can provide broad-range protection.
TABLE 2 Half maximal cross-reactive ELISA titers of anti-HA6 sera against HA of different strains
Antigen
% Identity with A/PR/8/34 HA Log10 (half-maximal ELISA titers)
HA1 HA2 HA6
Anti-H1HA6
sera
Anti-H1HA0HA6
sera
Anti-PR8
virus sera
Seasonal H1N1 New Caledonia/20/99 83 96 95 5.3 4.6 3.4
Pandemic H1N1 California/07/2009 75 92 90 5.0 3.7 2.6
H5N1 Vietnam/1203/2004 55 80 76 4.4 3.7 3.0
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H1HA6_PR8 and H1HA0HA6_PR8 also bound CR6261, albeit
with lesser affinity (Fig. 8B and C). The dissociation rates for both
H1HA6_PR8 and H1HA06_PR8 were found to be biphasic, in
contrast to rHA, which was monophasic. The relative amplitudes
of the fast and slow phases were approximately 0.15 and 0.85,
respectively, for both proteins. The gel filtration data (Fig. 4) sug-
gest that H1HA6_PR8 is largely trimeric while H1HA0HA6_PR8
is largely aggregated. It is likely that the biphasic dissociation rates
are due to heterogeneity in sample aggregation state. The relative
amplitudes suggest that slow dissociation results from trimer and
higher-order aggregates in the cases of H1HA6_PR8 and
H1HA0HA6_PR8, respectively. The fast dissociation likely results
from monomeric species in both cases.
Although H1HA6_PR8 protein is a trimer and H1HA0HA6_
PR8 is a higher-order aggregate, we have indicated analyte con-
centrations in trimer units in order to compare apparent Kd val-
ues. The binding stoichiometry known from the cocrystal
structure of CR6261 with HA is one monomer of the HA trimer
per paratope; however, when the analyte binds toCR6261 IgG that
is immobilized on the SPR chip,we anticipate that onemolecule of
the analyte will bind at a single immobilized paratope.
Sequence analysis. To identify conserved regions in the stem
of PR8, NC99, and Cal09 HAs, a pairwise sequence comparison
was done. Residue-wise conservationwasmapped onto the crystal
structure. Figure 9 shows several regions on the stem that are
conserved. Identical residues are in red, and nonidentical residues
are in blue. The conserved regions are likely targets for cross-
reactive antibodies that provide protection against PR8 challenge.
The highly conserved CR6261 epitope is one such epitope on the
stalk (Fig. 1A) that could mediate protection against several
strains and subtypes of flu viruses.
Several broadly neutralizing antibodies that bind to conserved
stem epitopes have been isolated recently (8, 21, 30, 31, 34). Some
of them bind to viruses of the H3 clade (mAb 12D1), while others
bind toHA from theH1 clade. Three neutralizing Abs that bind to
FIG 7 Competition of HA6 antisera with CR6261. Antisera from guinea pigs
immunized with stem immunogens (H1HA6_PR8, H1HA0HA6_PR8, or
H3HA6_HK68) were tested for competition binding to recombinant Viet/04
HA in the presence of 50 ng/ml of CR6261. Compared to naïve sera and sera
from animals immunized with an H3HA-derived stem immunogen
(H3HA6_HK68), H1HA6_PR8 antisera and H1HA0HA6_PR8 antisera
showed greater competition with CR6261.
TABLE 3 Kinetic parametersa for binding of recombinant HA A/California/07/09, H1HA6_PR8, and H1HA0HA6_PR8 to immobilized CR6261 as
determined by SPR
Analyte kon (M
1 s1) koff1 (s
1) koff2 (s
1) fa1 fa2 KD1 (M) KD2 (M)
rHA A/Cal/07/09 (1.37 0.6) 105 (8.7 4.7) 104 1.0 0.006 0.0008
H1HA6_PR8 (2.1 0.4) 103 (3.9 0.8) 102 (5.3 1.5) 104 0.18 0.04 0.82 0.04 19.2 2.7 0.26 0.1
H1HA0HA6_PR8 (1.9 0.9) 103 (1.7 0.2) 102 (4.0 1.7) 104 0.13 0.02 0.87 0.02 9.0 2.6 0.19 0.07
a kon is the rate constant for association. The rate constants for dissociation of H1HA6_PR8 and H1HA0HA6_PR8 are both biphasic; koff1 and koff2 are the rate constants for
dissociation, while fa1 and fa2 are the corresponding fractional amplitudes for phase 1 and phase 2, respectively. KD is the equilibrium dissociation constant. Data are representative
of two independent trials.
FIG 8 Binding of rHA A/California/09, H1HA6_PR8, and H1HA0HA6_PR8
to the broadly neutralizing Ab CR6261. Biacore sensorgram overlays of the
binding of 0.33 nM, 3.33 nM, 16.67 nM, 33.3 nM, and 66.67 nM rHA Califor-
nia/09 (A); 1.33M, 2.67M, 5.33M, and 10.67MH1HA6_PR8 (B); and
1.33 M, 2.67 M, 5.33 M, and 10.67 MH1HA0HA6_PR8 (C) at 25°C in
PBS (pH 7.4) containing 0.01% surfactant P20. Sensorgram overlays are
shown as dotted lines, and the corresponding fits are shown as solid lines. The
kinetic parameters for binding are given in Table 3. In all cases, analyte con-
centration increases from the bottom to the top curve.
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H1 and related HA proteins, CR6261, F10, and C179, bind to a
similar region of the HA stem. All the residues that are involved in
the binding of these Abs are included in the designed immuno-
gens. In the present case, although the immunogens bindCR6261,
the affinity is approximately 40-fold lower than that of HA. Better
immunogens that are capable of eliciting high titers of broadly
neutralizing antibodies could be designed by further minimizing
the protein to focus on the CR6261 epitope.
HA proteins from the different subtypes fall into two major
groups: H1HA falls in group 1, and H3HA falls in group 2 (10, 23,
30). Although broadly neutralizing antibodies such as CR6261,
F10, andC179 bind toHAproteins from group1, they do not bind
HAproteins of theH3 clade and hence do not neutralize viruses of
group 2, possibly because of glycosylation at the residue of Asp 38
of HA1 in A/HK/68 and the other group 2 HAs (H7, H10, and
H15) that is absent in group 1 HAs (8, 30). Structural analysis has
shown that HAs from the two groups differ in the stem region,
which is conserved within the clade. The presence of a conserved
stem epitope in the group 2 viruses, including the H3 viruses, has
been demonstrated (34). We previously found that a stem do-
main-based immunogen derived from A/HK/68 (an H3N2 virus)
failed to protect against A/PR/8/34 (H1N1) challenge in spite of
inducing broadly neutralizing 12D1-like antibodies (2). To date,
only one antibody capable of binding the stem region of HA from
viruses of both groups has been described (7). The presence of two
structural classes with respect to the stem domain of HA empha-
sizes the importance of having two different immunogens in order
to elicit antibodies that neutralize viruses from both groups of
influenza virus A.
Design of HA6 immunogens for other subtypes. One of the
primary reasons that H1HA6_PR8 could be expressed in the neu-
tral-pH formwas the presence of the two engineered Asp residues
in the loop connecting helices 4 and 5 of the PR8 HA (Fig. 1B and
C). Figure 10 shows the consensus sequences of this region in the
various subtypes of influenza HA. Shown in boxes are residues
FIG9 Sequence conservation between theHAproteins of PR8,NC99 (A), and
PR8, Cal09 (B) viruses. Residue-wise sequence conservation wasmapped onto
the HA crystal structure (PDB ID 1ru7) shown in spacefill representation.
Identical residues are in red, andnonidentical residues are in blue. TheCR6261
epitope is circled in white. The head domain of HA, which is not a part of the
design of H1HA6, is in pale green on the right of each panel to highlight
conserved regions in the stem domain constructs.
FIG 10 Sequence alignment of HA2 residues 57 to 75 from representative strains of the 16 different influenza A HA subtypes. Sequences have been taken from
the influenza virus resource at NCBI and numbered with the first residue of HA2 as residue 1 (1).Marked in the boxes are residues that are predicted to be buried
in the trimeric interface of the coiled coil at low pH: residues 63, 66, 70, and 73 of HA2, which would be at positions a, d, a, and d of the helical wheel, respectively.
These residues are in a relatively exposed loop in the neutral-pH structure. Hence, introduction of Asp residues at these positions would not affect the neutral pH
structure of the stem-derived immunogens.However, the low-pH conformationwould be greatly destabilized owing to the unfavorable burial of the chargedAsp
residues in the hydrophobic core of the coiled coil.
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that are expected to be exposed in the neutral-pH structure of the
stem-derived immunogens but buried in the low-pH structure of
HA. As can be seen, in all cases such residues exist, and it is there-
fore feasible to design similar immunogens for any subtype of
influenza A virus by mutating one or more of these residues. Such
immunogens may find application in future pandemics.
We have so far shown that it is possible to design stem-derived
immunogens for the seasonal H3N2 (2) and H1N1 (present
study) subtypes of the virus that confer protection against homol-
ogous challenge. Given the high similarity between the HA6 re-
gions of the seasonal and pandemic H1N1, the high cross-reactiv-
ity of H1N1 elicited sera with pandemic H1N1 HA, the ability of
H1HA6_Cal09 to protect against PR8 challenge, and the presence
ofCR6261-like antibodies in the polyclonal sera, it is likely that the
H1HA6_PR8 immunogen would confer protection against pan-
demic H1N1 viruses and other H1 viruses.
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